Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVANZ Cupressus Tolerability in Allergic Rhinoconjunctivitis
NCT02069535Phase 2Completed
- Sponsor
- ALK-Abelló
- Start
- Apr 2014
- Primary completion
- Nov 2014
- Modality
- Allergy Immunotherapy
- Countries
- 1
01
Overview
A Phase 2 trial of cupressus arizonica pollen in allergic rhinoconjunctivitis (ARC), sponsored by ALK-Abelló. Started Apr 2014; status: completed.
02
Drugs
cupressus arizonica pollen
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT02069535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02069535.